SG11201804223TA - OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF - Google Patents
OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOFInfo
- Publication number
- SG11201804223TA SG11201804223TA SG11201804223TA SG11201804223TA SG11201804223TA SG 11201804223T A SG11201804223T A SG 11201804223TA SG 11201804223T A SG11201804223T A SG 11201804223TA SG 11201804223T A SG11201804223T A SG 11201804223TA SG 11201804223T A SG11201804223T A SG 11201804223TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- guangdong
- dongyangguang
- dongguan
- zhen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau res., 00) (43) International Publication Date ..... ..sr.1 1 June 2017 (01.06.2017) WIPO I PCT ID Hit (10) 1111111111111111111 WO International Ell DION 2017/088759 Publication WHIM 11111 Ill Al Number RIIIIIIIIIIIIIII (51) International Patent Classification: (74) Agent: TSINGYIHUA INTELLECTUAL PROPERTY C07D 487/04 (2006.01) A61P 25/18 (2006.01) LLC; Room 301, Trade Building, Zhaolanyuan, Tsinghua A61K 31/517 (2006.01) A61P 1/00 (2006.01) University, Qinghuayuan, Haidian District, Beijing 100084 A61K 31/423 (2006.01) A61P 29/00 (2006.01) (CN). A61P 25/20 (2006.01) A61P 9/00 (2006.01) A61P 25/24 (2006.01) A61P 3/10 (2006.01) (81) Designated States (unless otherwise indicated, for every A61P 25/22 (2006.01) A61P 37/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/CN2016/106937 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 23 November 2016 (23.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 201510823712.8 23 November 2015 (23.11.2015) CN (84) Designated States (unless otherwise indicated, for every (71) Applicant: SUNSHINE LAKE PHARMA CO., LTD. kind of regional protection available): ARIPO (BW, GH, [CN/CN]; Northern Industrial Area, Songshan Lake, Dong- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, guan, Guangdong 523000 (CN). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors . ZHANG, Yingjun; Dongyangguang Hi-tech DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Park, Zhen An Road No.368, Shang Sha, Chang An Town, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Dongguan, Guangdong 523871 (CN). JIN, Chuanfei; SM, TR), OAPI BJ, CF, CG, CI, CM, GA, GN, GQ, (BF, Dongyangguang Hi-tech Park, Zhen An Road No.368, GW, KM, ML, MR, NE, SN, TD, TG). Shang Sha, Chang An Town, Dongguan, Guangdong Published: 523871 (CN) ZHANG, Ti; Dongyangguang Hi-tech Park, Zhen An Road No.368, Shang Sha, Chang An Town, — with international search report (Art 21(3)) Dongguan, Guangdong 523871 (CN). Il .4t C\ In IN GC GC C::: , IN 1-1 (54) Title: OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF 0 N (57) : The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceut- ical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease re- lated to orexin receptors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510823712 | 2015-11-23 | ||
PCT/CN2016/106937 WO2017088759A1 (en) | 2015-11-23 | 2016-11-23 | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804223TA true SG11201804223TA (en) | 2018-06-28 |
Family
ID=58762943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804223TA SG11201804223TA (en) | 2015-11-23 | 2016-11-23 | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
Country Status (8)
Country | Link |
---|---|
US (1) | US10370380B2 (en) |
EP (1) | EP3380475A4 (en) |
JP (1) | JP6936224B2 (en) |
CN (1) | CN106749269B (en) |
AU (1) | AU2016360245B2 (en) |
CA (1) | CA3005918C (en) |
SG (1) | SG11201804223TA (en) |
WO (1) | WO2017088759A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109988171A (en) * | 2017-12-29 | 2019-07-09 | 广东东阳光药业有限公司 | Octahydro pyrrolo- [3,4-c] azole derivatives and application thereof |
AU2020216214A1 (en) * | 2019-01-28 | 2021-07-08 | Suntory Holdings Limited | Composition for competitive inhibition of orexin receptors |
CN112876479B (en) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | Crystalline forms of octahydropyrrolo [3,4-c ] pyrrole derivatives |
CN112876481B (en) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | Crystalline forms of octahydropyrrolo [3,4-c ] pyrrole derivatives |
CN112876480B (en) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | Crystalline forms of octahydropyrrolo [3,4-c ] pyrrole derivatives |
WO2021104294A1 (en) * | 2019-11-29 | 2021-06-03 | Sunshine Lake Pharma Co., Ltd. | CRYSTAL FORMS OF OCTAHYDROPYRROLO [3,4-c] PYRROLE DERIVATIVES |
CN112876478B (en) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | Crystalline forms of octahydropyrrolo [3,4-c ] pyrrole derivatives |
CA3212319A1 (en) * | 2021-03-16 | 2022-09-22 | Hualing XIAO | Nitrogen-containing heterocyclic polycyclic compound, preparation method therefor, and application thereof |
WO2024056016A1 (en) * | 2022-09-14 | 2024-03-21 | 江苏豪森药业集团有限公司 | Free base crystal form of polycyclic compound of nitrogen-containing heterocycle, and preparation method therefor |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040029326A (en) | 2001-06-28 | 2004-04-06 | 스미스클라인비이참피이엘시이 | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
EP2001485B1 (en) | 2006-03-29 | 2015-09-09 | Merck Sharp & Dohme Corp. | Diazepan orexin receptor antagonists |
DK2049529T3 (en) | 2006-07-14 | 2010-11-29 | Merck Sharp & Dohme | Substituted diazepan-orexin receptor antagonists |
US8618102B2 (en) | 2006-07-14 | 2013-12-31 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
PE20081229A1 (en) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | DIAZEPAM OREXIN RECEPTOR ANTAGONISTS REPLACED |
CN101627028B (en) * | 2006-12-01 | 2013-03-27 | 默沙东公司 | Substituted diazepan compounds as orexin receptor antagonists |
EP2150114A4 (en) | 2007-05-18 | 2012-01-18 | Merck Sharp & Dohme | Oxo bridged diazepan orexin receptor antagonists |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
TW200911242A (en) | 2007-07-03 | 2009-03-16 | Glaxo Group Ltd | Novel compounds |
WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
WO2009058238A1 (en) | 2007-10-29 | 2009-05-07 | Merck & Co., Inc. | Substituted diazepan orexin receptor antagonists |
AU2008340421B2 (en) | 2007-12-21 | 2013-12-19 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
WO2009133522A1 (en) | 2008-04-30 | 2009-11-05 | Actelion Pharmaceuticals Ltd | Piperidine and pyrrolidine compounds |
US20100267730A1 (en) | 2008-10-09 | 2010-10-21 | Giuseppe Alvaro | Novel compounds |
US8093255B2 (en) | 2008-10-09 | 2012-01-10 | Glaxo Group Limited | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists |
EP2349269A4 (en) | 2008-10-21 | 2012-04-25 | Merck Sharp & Dohme | 2,5-disubstituted piperidine orexin receptor antagonists |
MX2011004551A (en) | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Isonicotinamide orexin receptor antagonists. |
JP2012509912A (en) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | New compounds |
JP2012509911A (en) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | New compounds |
EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
JP5847087B2 (en) * | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Fused heterocyclic compounds as orexin receptor modulators |
JP5848251B2 (en) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | Fused heterocyclic compounds as orexin receptor modulators |
EP2491038B1 (en) * | 2009-10-23 | 2016-04-06 | Janssen Pharmaceutica N.V. | Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators |
WO2012085857A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
EP2680697B1 (en) | 2011-03-03 | 2018-01-10 | Merck Sharp & Dohme Corp. | Process for the preparation of an orexin receptor antagonist |
WO2012145581A1 (en) * | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
JPWO2013005755A1 (en) | 2011-07-05 | 2015-02-23 | 大正製薬株式会社 | Methylpiperidine derivatives |
WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
AR088352A1 (en) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE |
US8940898B2 (en) | 2011-10-25 | 2015-01-27 | Merck Sharp & Dohme Corp. | Piperidinyl alkyne orexin receptor antagonists |
AR088692A1 (en) | 2011-11-08 | 2014-06-25 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF 2- (1,2,3-TRIAZOL-2-IL) BENZAMINE AND 3- (1,2,3-TRIAZOL-2-IL) PICOLINAMIDE |
MY169986A (en) | 2012-06-04 | 2019-06-19 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
CA2885180C (en) | 2012-10-10 | 2021-03-02 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
EP2908812A4 (en) | 2012-10-16 | 2016-04-20 | Merck Sharp & Dohme | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists |
WO2014066196A1 (en) | 2012-10-23 | 2014-05-01 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists |
EP2925321A4 (en) | 2012-11-27 | 2016-04-27 | Merck Sharp & Dohme | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
US9643955B2 (en) | 2012-12-20 | 2017-05-09 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists |
WO2014099697A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | 3-ester-4-substituted orexin receptor antagonists |
EP2934527A4 (en) | 2012-12-20 | 2016-07-13 | Merck Sharp & Dohme | 2-pyridyloxy-4-ester orexin receptor antagonists |
JP2014141480A (en) | 2012-12-28 | 2014-08-07 | Taisho Pharmaceutical Co Ltd | Pharmaceuticals containing methylpiperidine derivatives |
US9550786B2 (en) | 2013-01-16 | 2017-01-24 | Merck Sharp & Dohme Corp. | 4-fluoropiperidine orexin receptor antagonists |
WO2014137883A1 (en) | 2013-03-08 | 2014-09-12 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-ether orexin receptor antagonists |
TWI621618B (en) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | Substituted 2-azabicycles and their use as orexin receptor modulators |
TW201444821A (en) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | Substituted piperidine compounds and their use as orexin receptor modulators |
EP2988748A1 (en) | 2013-04-23 | 2016-03-02 | Merck Sharp & Dohme Corp. | Hydroxy-substituted orexin receptor antagonists |
US20160068514A1 (en) | 2013-04-23 | 2016-03-10 | Merck Sharp & Dohme Corp. | Halo and trifluoromethyl substituted orexin receptor antagonists |
EP2988747A1 (en) | 2013-04-23 | 2016-03-02 | Merck Sharp & Dohme Corp. | 2-hydroxymethyl-substituted orexin receptor antagonists |
WO2015018027A1 (en) | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Thiazole orexin receptor antagonists |
WO2015018029A1 (en) | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Oxazole orexin receptor antagonists |
CN104548097A (en) | 2013-10-14 | 2015-04-29 | 上海市肿瘤研究所 | Application of drug composition of tunicamycin and platinum anticancer drugs in treatment of liver cancer |
US9914721B2 (en) | 2013-12-04 | 2018-03-13 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
WO2015088865A1 (en) | 2013-12-09 | 2015-06-18 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-methyl orexin receptor antagonists |
WO2015088864A1 (en) | 2013-12-09 | 2015-06-18 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists |
US9732077B2 (en) | 2013-12-18 | 2017-08-15 | Merck Sharp & Dohme Corp. | Diazepane orexin receptor antagonists |
US9617246B2 (en) | 2013-12-18 | 2017-04-11 | Merck Sharp & Dohme Corp. | Thioether-piperidinyl orexin receptor antagonists |
US9556190B2 (en) | 2013-12-20 | 2017-01-31 | Merck Sharp & Dohme Corp. | Piperidinyloxy lactone orexin receptor antagonists |
US9676751B2 (en) | 2013-12-20 | 2017-06-13 | Merck Sharp & Dohme Corp. | 2-amino-3-ester-pyridl orexin receptor antagonists |
CA2940047A1 (en) | 2014-02-20 | 2015-08-27 | Takeda Pharmaceutical Company Limited | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists |
SG10201900536TA (en) | 2014-03-06 | 2019-02-27 | Shanghai Haiyan Pharmaceutical Tech Co Ltd | Piperidine derivatives as orexin receptor antagonist |
-
2016
- 2016-11-23 US US15/777,219 patent/US10370380B2/en active Active
- 2016-11-23 AU AU2016360245A patent/AU2016360245B2/en active Active
- 2016-11-23 JP JP2018526672A patent/JP6936224B2/en active Active
- 2016-11-23 SG SG11201804223TA patent/SG11201804223TA/en unknown
- 2016-11-23 EP EP16867982.7A patent/EP3380475A4/en active Pending
- 2016-11-23 CN CN201611056011.7A patent/CN106749269B/en active Active
- 2016-11-23 CA CA3005918A patent/CA3005918C/en active Active
- 2016-11-23 WO PCT/CN2016/106937 patent/WO2017088759A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA3005918A1 (en) | 2017-06-01 |
CN106749269B (en) | 2019-01-04 |
EP3380475A4 (en) | 2019-07-03 |
WO2017088759A1 (en) | 2017-06-01 |
CA3005918C (en) | 2023-10-17 |
CN106749269A (en) | 2017-05-31 |
US20180334460A1 (en) | 2018-11-22 |
AU2016360245A1 (en) | 2018-06-07 |
AU2016360245B2 (en) | 2020-07-09 |
US10370380B2 (en) | 2019-08-06 |
JP2018534338A (en) | 2018-11-22 |
EP3380475A1 (en) | 2018-10-03 |
JP6936224B2 (en) | 2021-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201804934PA (en) | Novel Compounds | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
SG11201909325RA (en) | 2-amino-quinoline derivatives | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
SG11201809874SA (en) | Systems and methods for locating a wireless device | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
SG11201903091VA (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
SG11201908894SA (en) | Ip6k inhibitors | |
SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor |